Roccaro et al. reported the difference in EV-miRNA
contents between MM-BM-MSCs and normal BM-MSCs [43]. EVs derived from MM-BM-MSCs have less tumour suppres- 5. Perspectives
sor miR-15a and higher levels of oncogenic proteins, Despite the fact that most studies have focused on tumour
cytokines and adhesion molecules, whereas normal-BM- cell- and BM-MSC-derived EVs, how EVs derived from
MSCs have the potential to inhibit MM cell growth. Their other types of cells act in the BME is largely unknown.
findings indicate a CAF-like ability of MM-BM-MSCs and Because a category of EVs includes components other than
the possible use of normal BM-MSCs for MM cell therapy. exosomes, including oncosomes, the type of EV and the
We also found that BM-MSCs from healthy young donors cells from which EVs originate should be clarified to eluci-
inhibit MM angiogenesis through EV-miRNA [44]. From date the precise mechanism of EV-mediated cell-cell
the aspect of CAFs, BM-MSC-derived EVs induce prolifer- communication.